Live Breaking News & Updates on Steven Lydeamore

Stay updated with breaking news from Steven lydeamore. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Immuron CEO Steven Lydeamore presented at AusBioInvest

MELBOURNE, Australia, Oct. 30, 2023 (GLOBE NEWSWIRE) Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian based and globally integrated bi. ....

Steven Lydeamore , Immuron Limited , Chief Executive Officer , Park Hyatt ,

Anatara Lifesciences Limited Company Summary & News ASX:ANR

Anatara Lifesciences Limited (ASX:ANR) is developing and commercialising innovative, evidence-based products for gastrointestinal health where there is significant unmet need. Anatara is a life sciences company with expertise in developing productsfor human and animal health. Anatara is focused on building a pipeline of human gastrointestinal health products. Underlying this product development program is our commitment to delivering real outcomes for patients and strong value for our shareholders. ....

David Brookes , Steven Lydeamore , Anatara Lifesciences Limited , Company Appendix , Company Stage , Anatara Lifesciences Ltd , Lifesciences Limited , Bowel Syndrome , David Brookes Read Full Article , Annual Report , Read Full Article , Chief Executive Officer , Full Article , Investor Presentation , Successful Piglet Study , Monthly Activities Report , Chair Transition , Non Executive Director , Chairman Read Full Article , Lifesciences Ltd , Progressing Towards First Human Clinical Studies , Asx Anr , Australian Stock Exchange , Sin Au000000anr0 ,

Immuron Announces Travelan® Clinical Study Cohort 2 commences

Highlights: Second cohort of 34 healthy volunteers enrolled in the Travelan® Clinical Trial Clinical Trial to examine a dosing regimen for Travelan® more suited to the US military has commenced. ....

United States , Steven Lydeamore , Mohamed Al Ibrahim , Immuron Limited , Clinical Research Facility Inpatient Unit , Clinical Trial , Principal Investigator Dr Mohamed Al Ibrahim ,

Immuron Announces Travelan® Clinical Study Cohort 2 commences - Immuron (NASDAQ:IMRN)

Highlights: Second cohort of 34 healthy volunteers enrolled in the Travelan® Clinical Trial Clinical Trial to examine a dosing regimen for Travelan® more suited to the US military has commenced the second ....

United States , Steven Lydeamore , Mohamed Al Ibrahim , Immuron Limited , Clinical Research Facility Inpatient Unit , Clinical Trial , Principal Investigator Dr Mohamed Al Ibrahim ,

Immuron achieves record quarterly Travelan® sales

Highlights: Record quarterly Travelan® sales of $1,550,240Total sales of A$1,565,767 in Q1, FY24 $1,508,933 increase on Q1, FY23 sales130% higher than pre-pandemic period Q1, FY20 sales . ....

United States , Steven Lydeamore , International Trade Administration Total , Australian Bureau Of Statistics , Immuron Limited , Therapeutic Goods Administration , South America , Central America ,